RNA Biomarker Could Be New Screen for Prostate Cancer.
Screening for prostate cancer currently involves testing a blood sample to see whether or not high concentrations of prostate-specific antigen (PSA) are present; however, many researchers consider this method to be imperfect. Soon, the PSA screening test may be a thing of the past as scientists have observed higher levels of a biomarker known as lncRNA in urine samples of prostate cancer patients when compared with samples provided by men without prostate cancer. Researcher Dr. Ranjan J. Perera explains, “We have identified a set of lncRNAs that appear to have an important role in prostate cancer diagnostics. The findings advance our understanding of the role of lncRNAs in cancer biology and, importantly, broaden the opportunity to use lncRNAs as biomarkers to detect prostate cancer.”
The Journal of Molecular Diagnostics, October 2014